Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The company is advancing its proprietary antiviral compound MGX-0024. The firm offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. The company has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.
MGRX stock price ended at $0.43 on 星期三, after rising 13.16%
On the latest trading day Jul 01, 2026, the stock price of MGRX rose by 13.16%, climbing from $0.37 to $0.43. During the session, the stock saw a volatility of 16.22%, with prices oscillating between a daily low of $0.37 and a high of $0.43. Notably, trading volume dropped by 224.8K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 554.3K shares were traded, equating to a market value of approximately $7.3M.